Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 105, Issue 3, 2008, Pages 333-341

  da Silva, Tarcília Aparecida ^a   Batista, Aline Carvalho ^b   Mendonça, Elismauro Francisco ^b   Leles, Cláudio Rodrigues ^c   Fukada, Sandra ^d   Cunha, Fernando Queiroz ^d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c Dental School   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AMELOBLASTOMA; ARTICLE; BIOSYNTHESIS; CELL COUNT; COMPARATIVE STUDY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; JAW TUMOR; METABOLISM; NONPARAMETRIC TEST; ODONTOGENIC TUMOR; OSTEOLYSIS; PATHOLOGY; STROMA CELL; TERATOMA; TOOTH DISEASE;

AMELOBLASTOMA; CELL COUNT; DENTIGEROUS CYST; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; JAW NEOPLASMS; NF-KAPPA B; ODONTOGENIC TUMORS; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; ROOT RESORPTION; STATISTICS, NONPARAMETRIC; STROMAL CELLS;

EID: 38949092904     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2007.06.009     Document Type: Article

References (30)

1. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
2. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95 (1998) 3597-3602
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Schneeweis L.A., Willard D., and Milla M.E. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280 (2005) 41155-41164
5. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
6. Taubman M.A., Valverde P., Han X., and Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol 76 11 Suppl (2005) 2033-2041
7. Philipsen H.P., Reichart P.A., Slootweg P.J., Slater L.J., Sciuba J.J., Eversole L.R., et al. Odontogenic tumors. In: Barnes L., Eveson J.W., Reichart P., and Sindransky D. (Eds). Pathology and genetics head and neck tumours. World Health Organization Classification of Tumours (2005), IARC Press, Lyon 283-328
8. Myoung H., Hong S.P., Hong S.D., Lee J.I., Lim C.Y., Choung P.H., et al. Odontogenic keratocyst: review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91 (2001) 328-333
9. Sandra F., Hendarmin L., Kukita T., Nakao Y., Nakamura N., and Nakamura S. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol 41 (2005) 637-644
10. Kumamoto H., and Ooya K. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med 33 (2004) 46-52
11. Tay J.Y., Bay B.H., Yeo J.F., Harris M., Meghji S., and Dheen S.T. Identification of RANKL in osteolytic lesions of the facial skeleton. J Dent Res 83 (2004) 349-353
12. Sandra F., Hendarmin L., and Nakamura S. Osteoprotegerin (OPG) binds with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 42 (2006) 415-420
13. Oka S., Kubota Y., Yamashiro T., Ogata S., Ninomiya T., Ito S., et al. Effects of positive pressure in odontogenic keratocysts. J Dent Res 84 (2005) 913-918
14. Kubota Y., Nitta S., Oka S., Nakagawa S., Ninomiya T., Shirasuna K., et al. Discrimination of ameloblastomas from odontogenic keratocysts by cytokine levels and gelatinase species of the intracystic fluids. J Oral Pathol Med 30 (2001) 421-427
15. Lee S.K., Gardner A.E., Kalinowski J.F., Jastrzebski S.L., and Lorenzo J.A. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38 (2006) 678-685
16. Liu X.H., Kirschenbaum A., Yao S., and Levine A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 146 (2005) 1991-1998
17. Schett G., Redlich K., Hayer S., Zwerina J., Bolon B., Dunstan C., et al. Osteoprotegerin protects against generalized bone loss in tumour necrosis factor-transgenic mice. Arthritis Rheum 48 (2003) 2042-2051
18. Damante J.H., and Fleury R.N. A contribution to the diagnosis of the small dentigerous cyst or the paradental cyst. Pesqui Odontol Bras 15 (2001) 238-246
19. Heider U., Hofbauer L.C., Zavrski I., Kaiser M., Jakob C., and Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 338 (2005) 687-693
20. Page G., and Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52 (2005) 2307-2312
21. So T., Lee S.W., and Croft M. Tumour necrosis factor/tumour necrosis factor receptor family members that positively regulate immunity. Int J Hematol 83 (2006) 1-11
22. Tobon-Arroyave S.I., Franco-Gonzalez L.M., Isaza-Guzman D.M., Florez-Moreno G.A., Bravo-Vasquez T., Castaneda-Pelaez D.A., et al. Immunohistochemical expression of RANK, GRalpha and CTR in central giant cell granuloma of the jaws. Oral Oncol 41 (2005) 480-488
23. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
24. Gonzalez-Suarez E., Branstetter D., Armstrong A., Dinh H., Blumberg H., and Dougall W.C. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 27 (2007) 1442-1454
25. Kanzaki H., Chiba M., Shimizu Y., and Mitani H. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res 80 (2001) 887-891
26. Rani C.S., and MacDougall M. Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Commun 3 (2000) 145-152
27. Sakata M., Shiba H., Komatsuzawa H., Fujita T., Ohta K., Sugai M., et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Miner Res 14 (1999) 1486-1492
28. Vernal R., Dezerega A., Dutzan N., Chaparro A., Leon R., Chandia S., et al. RANKL in human periapical granuloma: possible involvement in periapical bone destruction. Oral Dis 12 (2006) 283-289
29. Menezes R., Bramante C.M., Silva Paiva K.B., Letra A., Carneiro E., Fernando Zambuzzi W., et al. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 404-409
30. Hamdy N.A. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 3 (2005) 121-125